| Human immunodeficiency virus I infection
Descovy for PrEP vs Evotaz
Side-by-side clinical, coverage, and cost comparison for human immunodeficiency virus i infection.Deep comparison between: Descovy vs Evotaz with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsEvotaz has a higher rate of injection site reactions vs Descovy based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Evotaz but not Descovy, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Descovy
Evotaz
At A Glance
Oral
Daily
NRTI combination
Oral
Once daily
HIV-1 protease inhibitor with CYP3A inhibitor
Indications
- Human immunodeficiency virus I infection
- Human immunodeficiency virus I infection
Dosing
Human immunodeficiency virus I infection Adults and pediatric patients >=35 kg: one 200 mg/25 mg tablet once daily with or without food; pediatric patients 25 to <35 kg: one 200 mg/25 mg tablet once daily; 14 to <25 kg: one 120 mg/15 mg tablet once daily (with other antiretrovirals including DRV+COBI but not other PI/ritonavir or PI/cobicistat combinations); not recommended with eGFR 15-30 mL/min or <15 mL/min without chronic hemodialysis.
HIV-1 PrEP One 200 mg/25 mg tablet once daily orally with or without food in adults and adolescents >=35 kg with eGFR >=30 mL/min, or adults with eGFR <15 mL/min on chronic hemodialysis (dose after hemodialysis); not recommended with eGFR 15-30 mL/min or <15 mL/min without hemodialysis.
Human immunodeficiency virus I infection One tablet (atazanavir 300 mg/cobicistat 150 mg) orally once daily with food.
Contraindications
- Unknown or positive HIV-1 status when used for HIV-1 PrEP
- Clinically significant hypersensitivity (e.g., Stevens-Johnson syndrome, erythema multiforme, toxic skin eruptions) to any component
- Coadministration with strong CYP3A4 inducers
- Coadministration with drugs highly dependent on CYP3A or UGT1A1 for clearance with narrow therapeutic indices
- Coadministration with alfuzosin
- Coadministration with ranolazine
- Coadministration with dronedarone
- Coadministration with carbamazepine, phenobarbital, phenytoin
- Coadministration with colchicine in patients with hepatic or renal impairment
- Coadministration with rifampin
- Coadministration with apalutamide, encorafenib, irinotecan, ivosidenib
- Coadministration with lurasidone, pimozide
- Coadministration with dihydroergotamine, ergotamine, methylergonovine
- Coadministration with elbasvir/grazoprevir, glecaprevir/pibrentasvir
- Coadministration with St. John's wort (Hypericum perforatum)
- Coadministration with drospirenone/ethinyl estradiol
- Coadministration with lomitapide, lovastatin, simvastatin
- Coadministration with nevirapine
- Coadministration with sildenafil when used for pulmonary arterial hypertension
- Coadministration with indinavir
- Coadministration with triazolam, orally administered midazolam
Adverse Reactions
Most common (>=10%) Nausea (in antiretroviral treatment-naive adults with HIV-1 receiving FTC+TAF with EVG+COBI)
Serious Severe acute exacerbations of hepatitis B, immune reconstitution syndrome, new onset or worsening renal impairment, lactic acidosis/severe hepatomegaly with steatosis
Postmarketing Angioedema, urticaria, rash, acute renal failure, acute tubular necrosis, proximal renal tubulopathy, Fanconi syndrome
Most common (>=5%) Jaundice, rash
Serious Cardiac conduction abnormalities, rash, effects on serum creatinine, new onset or worsening renal impairment, chronic kidney disease, nephrolithiasis, cholelithiasis, hepatotoxicity, hyperbilirubinemia
Pharmacology
Dual HIV NRTI combination; emtricitabine (FTC) and tenofovir alafenamide (TAF) each inhibit HIV-1 reverse transcriptase via nucleotide analog chain termination after intracellular phosphorylation, with TAF serving as a prodrug converted intracellularly to tenofovir and then to the active metabolite tenofovir diphosphate.
EVOTAZ is a fixed-dose combination of atazanavir, an HIV-1 protease inhibitor that prevents viral Gag and Gag-Pol polyprotein processing, and cobicistat, a CYP3A inhibitor that increases atazanavir systemic exposure.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Descovy
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (1/12) · Qty limit (11/12)
Evotaz
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Descovy
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (6/8)
Evotaz
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Descovy
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Evotaz
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0
Gilead Advancing Access Patient Assistance Program/Medication Assistance Program (PAP/MAP)Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
DescovyView full Descovy profile
EvotazView full Evotaz profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.